{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:10:49Z","timestamp":1780445449051,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271107"],"award-info":[{"award-number":["82271107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.bbrc.2024.150065","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T06:21:53Z","timestamp":1715062913000},"page":"150065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Suppression of retinal neovascularization by intravitreal injection of cryptotanshinone"],"prefix":"10.1016","volume":"720","author":[{"given":"Yang","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiling","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juxue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2024.150065_bib1","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular pathogenesis of retinal and choroidal vascular diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150065_bib2","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H","article-title":"Retinal and choroidal neovascularization","volume":"184","author":"Campochiaro","year":"2000","journal-title":"J. Cell. Physiol."},{"issue":"6","key":"10.1016\/j.bbrc.2024.150065_bib3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.preteyeres.2010.05.003","article-title":"Animal models of choroidal and retinal neovascularization","volume":"29","author":"Grossniklaus","year":"2010","journal-title":"Prog. Retin. Eye Res."},{"issue":"2","key":"10.1016\/j.bbrc.2024.150065_bib4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.retram.2019.01.005","article-title":"Update of inflammatory proliferative retinopathy: ischemia, hypoxia and angiogenesis","volume":"67","author":"Aouiss","year":"2019","journal-title":"Curr. Res. Transl. Med."},{"key":"10.1016\/j.bbrc.2024.150065_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.001","article-title":"Retinal vasculature development in health and disease","volume":"63","author":"Selvam","year":"2018","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.bbrc.2024.150065_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.preteyeres.2008.05.001","article-title":"Vascular endothelial growth factor in eye disease","volume":"27","author":"Penn","year":"2008","journal-title":"Prog. Retin. Eye Res."},{"issue":"17","key":"10.1016\/j.bbrc.2024.150065_bib7","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.7150\/thno.26203","article-title":"G\u03b1i1 and G\u03b1i3mediate VEGF-induced VEGFR2 endocytosis, signaling and angiogenesis","volume":"8","author":"Sun","year":"2018","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.bbrc.2024.150065_bib8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41420-023-01717-2","article-title":"Mechanistic insights into the alterations and regulation of the AKT signaling pathway in diabetic retinopathy","volume":"9","author":"Li","year":"2023","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.bbrc.2024.150065_bib9","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"7","key":"10.1016\/j.bbrc.2024.150065_bib10","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"issue":"10","key":"10.1016\/j.bbrc.2024.150065_bib11","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14712598.2022.2100694","article-title":"Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? Expert","volume":"22","author":"Uludag","year":"2022","journal-title":"Opin. Biol. Ther."},{"issue":"2","key":"10.1016\/j.bbrc.2024.150065_bib12","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11739-019-02253-7","article-title":"Intravitreal anti-VEGF agents and cardiovascular risk","volume":"15","author":"Porta","year":"2020","journal-title":"Intern.Emerg.Med."},{"issue":"12","key":"10.1016\/j.bbrc.2024.150065_bib13","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/DMSO.S214098","article-title":"Burden of treatment among patients undergoing intravitreal injections for diabetic macular oedema in Australia","volume":"19","author":"Spooner","year":"2019","journal-title":"Diabetes Metab.Syndr.Obes."},{"key":"10.1016\/j.bbrc.2024.150065_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2020.104633","article-title":"A review of its pharmacology activities and molecular mechanisms","volume":"145","author":"Wu","year":"2020","journal-title":"Fitoterapia"},{"key":"10.1016\/j.bbrc.2024.150065_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2023.116697","article-title":"Bioactive components and molecular mechanisms of Salvia miltiorrhiza Bunge in promoting blood circulation to remove blood stasis","volume":"317","author":"Wei","year":"2023","journal-title":"J. Ethnopharmacol."},{"issue":"Pt 3","key":"10.1016\/j.bbrc.2024.150065_bib16","article-title":"Mechanism of cryptotanshinone to improve endocrine and metabolic functions in the endometrium of PCOS rats","volume":"319","author":"Liu","year":"2024","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bbrc.2024.150065_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115956","article-title":"Cryptotanshinone suppresses ovarian cancer via simultaneous inhibition of glycolysis and oxidative phosphorylation","volume":"170","author":"Wang","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1\u20132","key":"10.1016\/j.bbrc.2024.150065_bib18","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11010-015-2424-0","article-title":"A Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro","volume":"406","author":"Li","year":"2015","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbrc.2024.150065_bib19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mvr.2016.12.011","article-title":"Cryptotanshinone inhibits VEGF-induced angiogenesis by targeting the VEGFR2 signaling pathway","volume":"111","author":"Xu","year":"2017","journal-title":"Microvasc. Res."},{"issue":"2","key":"10.1016\/j.bbrc.2024.150065_bib20","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/emm.2005.18","article-title":"Cryptotanshinone but not tanshinone IIA inhibits angiogenesisin vitro","volume":"37","author":"Hur","year":"2005","journal-title":"Exp. Mol. Med."},{"issue":"11","key":"10.1016\/j.bbrc.2024.150065_bib21","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/nprot.2009.187","article-title":"Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis","volume":"4","author":"Connor","year":"2009","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.bbrc.2024.150065_bib22","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrm3176","article-title":"Molecular control of endothelial cell behaviour during blood vessel morphogenesis","volume":"12","author":"Herbert","year":"2011","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7070","key":"10.1016\/j.bbrc.2024.150065_bib23","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/nature04482","article-title":"Retinal angiogenesis in development and disease","volume":"438","author":"Gariano","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2024.150065_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"issue":"4","key":"10.1016\/j.bbrc.2024.150065_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr. Rev."},{"issue":"10","key":"10.1016\/j.bbrc.2024.150065_bib26","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA. Ophthalmol."},{"key":"10.1016\/j.bbrc.2024.150065_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100906","article-title":"Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities","volume":"82","author":"Mettu","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.bbrc.2024.150065_bib28","article-title":"The signaling pathways of traditional Chinese medicine in treating diabetic retinopathy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2024.150065_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110852","article-title":"A review of traditional Chinese medicine on treatment of diabetic retinopathy and involved mechanisms","volume":"132","author":"Ai","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2024.150065_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105384","article-title":"Cryptotanshinone specifically suppresses NLRP3 inflammasome activation and protects against inflammasome-mediated diseases","volume":"164","author":"Liu","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2024.150065_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.979634","article-title":"Anticancer potential of cryptotanshinone on breast cancer treatment; A narrative review","volume":"13","author":"Dalil","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2024.150065_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111332","article-title":"A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen","volume":"137","author":"Li","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2024.150065_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104307","article-title":"Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways","volume":"147","author":"Zhang","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bbrc.2024.150065_bib34","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"issue":"3","key":"10.1016\/j.bbrc.2024.150065_bib35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1002\/biof.1824","article-title":"Wnt inhibitory 1 ameliorates neovascularization and attenuates photoreceptor injury in an oxygen-induced retinopathy mouse model","volume":"48","author":"Tan","year":"2022","journal-title":"Biofactors"},{"issue":"16","key":"10.1016\/j.bbrc.2024.150065_bib36","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.3390\/molecules25163602","article-title":"Neuroprotective effects of cryptotanshinone in a direct reprogramming model of Parkinson's disease","volume":"25","author":"Lee","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bbrc.2024.150065_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s12272-020-01242-1","article-title":"Ameliorates placental oxidative stress and inflammation in mice with gestational diabetes mellitus","volume":"43","author":"Wang","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"issue":"6","key":"10.1016\/j.bbrc.2024.150065_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/iovs.63.6.13","article-title":"A novel hypoxia-inducible factor 1\u03b1 inhibitor KC7F2 attenuates oxygen-induced retinal neovascularization","volume":"63","author":"Tang","year":"2022","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150065_bib39","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12906-019-2739-6","article-title":"Alkaloid extract of Corydalis yanhusuo inhibits angiogenesis via targeting vascular endothelial growth factor receptor signaling","volume":"19","author":"Wan","year":"2019","journal-title":"BMC Compl. Alternative Med."},{"issue":"2","key":"10.1016\/j.bbrc.2024.150065_bib40","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/med.20101","article-title":"STAT3: a critical transcription activator in angiogenesis","volume":"28","author":"Chen","year":"2008","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.bbrc.2024.150065_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 signaling in immunity. Cytokine","volume":"31","author":"Hillmer","year":"2016","journal-title":"Growth.Factor.Rev."},{"issue":"1","key":"10.1016\/j.bbrc.2024.150065_bib42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","article-title":"Targeting STAT3 in cancer immunotherapy","volume":"19","author":"Zou","year":"2020","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.bbrc.2024.150065_bib43","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.1161\/ATVBAHA.120.314567","article-title":"Hyaloid vasculature as a major source of STAT3+ (signal transducer and activator of transcription 3) myeloid cells for pathogenic retinal neovascularization in oxygen-induced retinopathy","volume":"40","author":"Hombrebueno","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24006016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X24006016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T05:37:27Z","timestamp":1717738647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X24006016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":43,"alternative-id":["S0006291X24006016"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150065","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of retinal neovascularization by intravitreal injection of cryptotanshinone","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2024.150065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"150065"}}